NYSE:NVS Novartis (NVS) Stock Price, News & Analysis $117.62 +0.49 (+0.42%) (As of 08/21/2024 ET) Add Compare Share Share Today's Range$116.93▼$117.7550-Day Range$104.93▼$117.6252-Week Range$92.19▼$117.75Volume711,792 shsAverage Volume1.20 million shsMarket Capitalization$240.42 billionP/E Ratio15.87Dividend Yield2.07%Price Target$118.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Novartis alerts: Email Address Novartis MarketRank™ Stock AnalysisAnalyst RatingHold2.14 Rating ScoreUpside/Downside0.4% Upside$118.13 Price TargetShort InterestHealthy0.29% of Float Sold ShortDividend StrengthModerateBased on Four FactorsSustainabilityN/ANews Sentiment0.22Based on 8 Articles This WeekInsider TradingN/AProj. Earnings Growth11.02%From $7.44 to $8.26 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.31 out of 5 starsMedical Sector759th out of 924 stocksPharmaceutical Preparations Industry352nd out of 426 stocks 1.1 Analyst's Opinion Consensus RatingNovartis has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 2 buy ratings, 4 hold ratings, and 1 sell rating.Amount of Analyst CoverageNovartis has only been the subject of 4 research reports in the past 90 days.Read more about Novartis' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.29% of the float of Novartis has been sold short.Short Interest Ratio / Days to CoverNovartis has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Novartis has recently decreased by 9.95%, indicating that investor sentiment is improving significantly. Previous Next 2.5 Dividend Strength Dividend YieldNovartis pays a meaningful dividend of 2.12%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthNovartis does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Novartis is 32.79%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Novartis will have a dividend payout ratio of 29.42% next year. This indicates that Novartis will be able to sustain or increase its dividend.Read more about Novartis' dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NVS. Previous Next 1.2 News and Social Media Coverage News SentimentNovartis has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Novartis this week, compared to 10 articles on an average week.Search InterestOnly 7 people have searched for NVS on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Novartis to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Novartis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.01% of the stock of Novartis is held by insiders.Percentage Held by InstitutionsOnly 13.12% of the stock of Novartis is held by institutions.Read more about Novartis' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Novartis are expected to grow by 11.02% in the coming year, from $7.44 to $8.26 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novartis is 15.87, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.90.Price to Earnings Ratio vs. SectorThe P/E ratio of Novartis is 15.87, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 133.84.Price to Earnings Growth RatioNovartis has a PEG Ratio of 1.69. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNovartis has a P/B Ratio of 5.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Novartis' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThis Crypto Is Set to Explode in AugustWith the 2024 Bitcoin Halving, there's a potential HUGE bull run for altcoins. While everyone's chasing the latest DeFi craze or the next hot meme coin, the savviest investors are quietly positioning themselves for a different kind of explosion. This year's Bitcoin halving bull run is about to unleash a tidal wave in a completely undervalued sector of the crypto market.Click here to review my research and see how this coin is at the center of a disruptive blockchain s About Novartis Stock (NYSE:NVS)Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Read More NVS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVS Stock News HeadlinesAugust 18, 2024 | fool.com2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200August 18, 2024 | americanbankingnews.comBrokerages Set Novartis AG (NYSE:NVS) Target Price at $118.13August 22, 2024 | Colonial Metals (Ad)Wanted Dead: PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.August 15, 2024 | finance.yahoo.comUS judge denies initial attempt by Novartis to block generic Entresto launchAugust 15, 2024 | msn.comBristol Myers, Novartis react as Medicare prices for key drugs announcedAugust 14, 2024 | msn.comJudge Rules Against Novartis' Effort To Halt Generic Launch Of Its Top-Selling Heart Disease DrugAugust 13, 2024 | msn.comFed court rules against Novartis in generic Entresto case: reportAugust 8, 2024 | finance.yahoo.comFDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney DiseaseAugust 22, 2024 | Colonial Metals (Ad)Wanted Dead: PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.August 8, 2024 | msn.comNovartis says FDA gives accelerated approval for kidney-disease treatmentAugust 8, 2024 | markets.businessinsider.comNovartis Receives FDA Accelerated Approval For Fabhalta As First Complement Inhibitor For IgANAugust 7, 2024 | prnewswire.comNovartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)August 7, 2024 | globenewswire.comNovartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)August 7, 2024 | finance.yahoo.comPipeline Moves: Novartis terminates Phase II ALS trial after benefit-risk worryAugust 7, 2024 | reuters.comUS FDA approves Novartis' kidney disease drugAugust 6, 2024 | msn.comNovartis AG (NVS): The Best Organ Transplant and Diagnosis Stock According to Street Analysts?August 1, 2024 | msn.comNovartis sues FDA for approving Entresto genericJuly 26, 2024 | reuters.comUS court finds ‘robust’ anti-fraud safeguards in Novartis settlementSee More Headlines Receive NVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/18/2024Today8/21/2024Next Earnings (Estimated)10/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:NVS CUSIPN/A CIK1114448 Webwww.novartis.com Phone(161) 324-1111Fax41-61-324-7826Employees76,057Year Founded1996Price Target and Rating Average Stock Price Target$118.13 High Stock Price Target$122.50 Low Stock Price Target$114.00 Potential Upside/Downside+0.4%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$7.41 Trailing P/E Ratio15.87 Forward P/E Ratio15.81 P/E Growth1.69Net Income$14.85 billion Net Margins33.76% Pretax Margin22.75% Return on Equity34.56% Return on Assets14.24% Debt Debt-to-Equity Ratio0.47 Current Ratio0.93 Quick Ratio0.72 Sales & Book Value Annual Sales$45.44 billion Price / Sales5.29 Cash Flow$11.40 per share Price / Cash Flow10.32 Book Value$22.87 per share Price / Book5.14Miscellaneous Outstanding Shares2,044,000,000Free Float2,043,796,000Market Cap$240.42 billion OptionableOptionable Beta0.57 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Vasant Narasimhan M.D. (Age 48)Chief Executive Officer Comp: $8.01MMr. Harry Kirsch (Age 59)Chief Financial Officer Comp: $3.99MMr. Victor Bulto (Age 46)President of US Comp: $3.28MDr. Patrick Horber M.D. (Age 54)President of International Comp: $7.31MDr. Steffen Lang Ph.D. (Age 57)President of Operations Comp: $2.34MPaul PenepentHead of Group Financial Reporting and AccountingMs. Sloan SimpsonGlobal Head of Investor RelationsDr. Klaus Moosmayer Ph.D. (Age 56)Chief Ethics, Risk & Compliance Officer Comp: $1.55MMs. Karen L. Hale (Age 56)Chief Legal Officer Comp: $2.34MDr. Robert Kowalski Pharm.D. (Age 56)Chief People & Organization Officer Comp: $2.1MMore ExecutivesKey CompetitorsNovo Nordisk A/SNYSE:NVOAstraZenecaNASDAQ:AZNSanofiNASDAQ:SNYGSKNYSE:GSKTakeda PharmaceuticalNYSE:TAKView All CompetitorsInstitutional OwnershipTruist Financial CorpSold 5,657 shares on 8/21/2024Ownership: 0.037%Granite Bay Wealth Management LLCBought 8,505 shares on 8/21/2024Ownership: 0.000%B. Riley Wealth Advisors Inc.Sold 2,075 shares on 8/19/2024Ownership: 0.001%EP Wealth Advisors LLCSold 1,311 shares on 8/19/2024Ownership: 0.001%Kimelman & Baird LLCBought 6,900 shares on 8/19/2024Ownership: 0.000%View All Institutional Transactions Should I Buy Novartis Stock? NVS Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Novartis AG: Novartis AG has recently launched a groundbreaking new drug that is expected to significantly boost revenue and profits. The company's stock price has been steadily increasing over the past year, indicating positive investor sentiment. Novartis AG has a strong pipeline of innovative products in development, which could drive future growth. Recent acquisitions by Novartis AG have expanded its market reach and diversified its product portfolio. Novartis AG has a solid financial position with healthy cash reserves and low debt levels, providing stability and flexibility for future investments. Cons Investors should be bearish about investing in Novartis AG for these reasons: There is potential regulatory risk associated with the pharmaceutical industry, which could impact Novartis AG's operations and profitability. Competition in the healthcare sector is intense, and Novartis AG may face challenges in maintaining market share and pricing power. Global economic uncertainties and geopolitical tensions could affect Novartis AG's international operations and revenue streams. The healthcare sector is subject to rapid technological advancements and changing consumer preferences, posing risks of product obsolescence for Novartis AG. Fluctuations in currency exchange rates could impact Novartis AG's financial performance, especially in markets with high volatility. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, August 18, 2024. Please send any questions or comments about these Novartis pros and cons to contact@marketbeat.com. NVS Stock Analysis - Frequently Asked Questions How have NVS shares performed this year? Novartis' stock was trading at $100.97 at the start of the year. Since then, NVS shares have increased by 16.5% and is now trading at $117.62. View the best growth stocks for 2024 here. How were Novartis' earnings last quarter? Novartis AG (NYSE:NVS) announced its quarterly earnings results on Thursday, July, 18th. The company reported $1.97 earnings per share for the quarter, beating analysts' consensus estimates of $1.87 by $0.10. The firm earned $12.87 billion during the quarter, compared to the consensus estimate of $12.24 billion. Novartis had a net margin of 33.76% and a trailing twelve-month return on equity of 34.56%. What is Vas Narasimhan's approval rating as Novartis' CEO? 938 employees have rated Novartis Chief Executive Officer Vas Narasimhan on Glassdoor.com. Vas Narasimhan has an approval rating of 95% among the company's employees. This puts Vas Narasimhan in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Does Novartis have any subsidiaries? Novartis subsidiaries include these companies: Gyroscope Therapeutics, Arctos Medical, Cellerys, Cadent Therapeutics, Vedere Bio, Vedere Bio ll, Amblyotech, and more. Who are Novartis' major shareholders? Novartis' top institutional shareholders include Primecap Management Co. CA (0.60%), Dimensional Fund Advisors LP (0.36%), Renaissance Technologies LLC (0.12%) and Principal Financial Group Inc. (0.12%). How do I buy shares of Novartis? Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Novartis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), Walt Disney (DIS) and Gilead Sciences (GILD). This page (NYSE:NVS) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredSilver Grab of the Decade?In a groundbreaking move, J.P. Morgan now possesses the largest amount of physical silver in recorded history…...Colonial Metals | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novartis AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Novartis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
